XML 46 R27.htm IDEA: XBRL DOCUMENT v3.10.0.1
Collaboration and License Agreements - Janssen Pharmaceuticals, Inc - Additional Information (Detail)
1 Months Ended 3 Months Ended
Oct. 03, 2018
USD ($)
Obligation
Oct. 31, 2018
USD ($)
Target
$ / shares
shares
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Proceeds from the issuance of common stock     $ 60,521,729  
Revenues     34,657,896 $ 3,509,821
Collaboration and License agreements        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Initial transaction price $ 197,800,000      
JJDC | Common Stock Purchase Agreement        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Shares issued | shares   3,260,869    
Stock issued, price per share | $ / shares   $ 23.00    
Janssen and JJDC        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Revenues     34,700,000  
Contract assets     3,200,000  
Contract liabilities     $ 158,100,000  
Janssen and JJDC | Common Stock Purchase Agreement        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Shares issued | shares   3,260,869    
Stock issued, price per share | $ / shares   $ 23.00    
Proceeds from the issuance of common stock   $ 75,000,000    
Janssen and JJDC | Collaboration and License agreements        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Proceeds from the issuance of common stock   75,000,000    
Cash received as due under collaboration agreement   175,000,000    
Janssen        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Number of distinct performance obligations | Obligation 1      
Janssen | Common Stock Purchase Agreement        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Agreement date Oct. 03, 2018      
Janssen | License Agreement        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Agreement date Oct. 03, 2018      
Janssen | License Agreement | Maximum        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Development, regulatory and sales milestones payments   $ 1,600,000,000    
Janssen | Research Collaboration and Option Agreement        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Agreement date Oct. 03, 2018      
Number of additional targets for development, regulatory and sales milestone payments | Target   3    
Janssen | Collaboration Agreement | Maximum        
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]        
Development, regulatory and sales milestones payments   $ 1,900,000,000